Sage Capital Advisors,Llc Dermata Therapeutics, Inc. Transaction History

Sage Capital Advisors,Llc

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Jul 06, 2022	BUY	$115.2 - $319.2 $1.38 Million - $3.83 Million	12,000 New	12,000 $8,000
Q1 2022 Apr 11, 2022	SELL	$223.2 - $571.2 $2.68 Million - $6.85 Million	-12,000 Closed	0 $0
Q4 2021 Jan 20, 2022	BUY	$374.4 - $1500.0 $4.49 Million - $18 Million	12,000 New	12,000 $20,000

Ticker DRMA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 10,102,200
Market Cap $11.5M
Description
Dermata Therapeutics, Inc., a clinical-stage biotechnology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe ...

Get notified when there are updates to the investment portfolio of Sage Capital Advisors,Llc, based on Form 13F filings with the SEC.

Stay updated on Sage Capital Advisors,Llc with notifications on news.